Chemotactic responsiveness is crucial to neutrophil recruitment to sites of infection. During chemotaxis, highly divergent cytoskeletal programs are executed at the leading and trailing edge of motile neutrophils. The Rho family small GTPases play critical roles in cell migration, and recent work has focused on elucidating the specific roles played by Rac1, Rac2, Cdc42 and Rho during cellular chemotaxis. Rac GTPases regulate actin polymerization and extension of the leading edge, whereas Rho GTPases control myosin-based contraction of the trailing edge. Rac and Rho signalling are thought to crosstalk with one another, and previous research has focused on mutual inhibition of Rac and Rho signalling during chemotaxis. Indeed, polarization of neutrophils has been proposed to involve the activity of a negative feedback system where Rac activation at the front of the cell inhibits local Rho activation, and vice versa.
Introduction
The Rho subfamily of ras-related small guanosine triphosphatases (GTPases) are important regulators of events downstream of membrane receptor activation, including the regulation of actin and myosin cytoskeletal dynamics and directed cell motility 1 .
Previous studies have confirmed that Cdc42 and Rac GTPases play crucial roles in neutrophil chemotaxis through the regulation of cell polarization and actin assembly, two critical events that occur at the leading edge during chemotaxis 1 . Effective chemotaxis also requires the neutrophil to de-attach matrix contacts and retract the rear of the cell (the uropod) 2 . The GTPase Rho has been implicated in the regulation of uropod retraction through myosin-mediated contractility 3, 4 .
The Rac1 and Rac2 isoforms have more than 90% homology at the amino acid level, and these GTPases are known to play multiple roles in hematopoietic cell function [5] [6] [7] [8] [9] . Recent work has focused on the unique and separate roles of these closely related proteins in blood cell activity. Notably, neutrophils derived from Rac2 null mice exhibit marked decreases in their ability to chemotax in response to multiple chemoattractant stimuli [6] [7] [8] . This defect is accompanied by a severe impairment in F-actin assembly at the leading edge. Rac1-deficient neutrophils, while able to undergo normal chemokinesis, exhibit a significant but more modest inability to migrate up chemoattractant gradients 9 .
These cells are characterized by the formation of multiple unstable pseudopods, as well as a substantial uropod retraction defect.
Neutrophils and related leukocytes show a strong inherent ability to polarize in the presence of chemoattractants 10 and must maintain stable polarity for efficient directed migration. Bourne and colleagues have put forth the idea of locally incompatible
For personal use only. by on April 12, 2008 . www.bloodjournal.org From Rac-organized leading edge ""frontness"" and rear Rho-orchestrated ""backness"" programs that generate cell polarization through mutual inhibition 11 . These studies suggested that Rac-mediated ""frontness"" acts to locally suppress Rho activation and ""backness"", leading to establishment of cell polarity. However the mechanisms proposed to regulate "frontness" are inherently unstable, as formation of the pseudopod in an autocatalytic manner could potentially lead to the spread of ""frontness"" over the entire cell. Here we demonstrate that Rac not only locally inhibits the ""backness""
program at the leading edge, but is also globally required for generation of Rho-myosin mediated ""backness"" at the trailing edge of motile neutrophils. Further, this function appears to primarily be mediated by Rac1, but not Rac2, as determined in neutrophils genetically deficient in individual Rac isoforms. The regulation by Rac of uropodassociated Rho activity identifies a unique mechanism for the maintenance of stable cell polarity during chemotaxis.
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Results

Neutrophils deficient in Rac1 activity exhibit chemotaxis and tail retraction defects.
We previously reported that in chemotactically-responding primary human neutrophils, Rac activation occurs both at the leading edge and in the uropod of migrating cells 12 . These results suggested the possibility that Rac could play a regulatory role in retraction of the uropod. Indeed, we showed that low-level expression of a dominant negative Rac1T17N mutant (ie. at equal to or less than endogenous levels of Rac) decreased chemotactic motility (Fig.1A ) in association with failure to efficiently retract the uropod (Fig.1B ,C and Supplemental Movie #2) (see 12 and Fig.3 within as well).
While the migration speed of these cells was decreased due to the observed defects in tail retraction, they still were apparently able to sense the gradient of chemoattractant, as evident by their orientation towards the point source of fMLP and their attempts to move towards this source (see Supplemental Movie #2). The effects of Rac1T17N expression were concentration-dependent, as expression at levels 2-3 fold greater than endogenous Rac induced a substantial loss of leading edge formation, associated with the redistribution of F-actin around the cell periphery 12 . We cannot exclude that the effect of Rac1T17N is mediated via inhbition of Rac2, which is the predominant form of Rac in human neutrophils, representing 90-95% of total Rac 5 .
As noted, transduction of dominant negative Rac1T17N vs Rac2T17N proteins into human neutrophils does not allow us to cleanly distinguish between possible differences in the contribution of Rac1 vs Rac2 to the uropod retraction defect (see Discussion). In order to assess whether Rac1 or Rac2 (or both) potentially regulate tail retraction, we took advantage of neutrophils derived from Rac1 and Rac2 null mice,
For personal use only. by on April 12, 2008 . www.bloodjournal.org From genetically deficient in these individual GTPases. As noted previously 9 , Rac1 null mouse neutrophils also exhibit an unusual elongated morphology during chemotaxis, remarkably similar to that of human neutrophils expressing dominant negative Rac1 (Fig.1D) . Also like human neutrophils expressing Rac1T17N, the Rac1 null leukocytes develop an oriented leading edge, but they exhibit an apparent defect in uropod retraction. This phenotype is not observed in the Rac2 null cells (Fig.1D) .
Rho also regulates neutrophil tail retraction.
Interestingly, a similar effect on tail retraction was observed upon introduction of dominant negative RhoT19N into human neutrophils: cells were no longer able to effectively chemotax in response to a point source of fMLP (Fig.1A) . Like neutrophils expressing Rac1T17N, the cells appeared to respond to the chemotactic gradient (as evidenced by orientation toward the point source), but were unable to efficiently withdraw their tails, which became elongated in appearance ( Fig.1B,C ; Suppl. Movie #3).
Cells expressing constitutively active RhoAG14V were also deficient in their ability to chemotax (Fig.1A) . In this case, however, the cells appeared rounded and were characterized by formation of random, unstable pseudopods (Suppl. Movie #6). This inability to form stable pseudopods prevented the cells from maintaining a polarized morphology and inhibited effective directional migration. The latter phenotype is consistent with the proposed role of Rho in regulating "backness", and 11 have reported a similar observation. Fig.2A) , as well as in the fraction of cells exhibiting detectable Rho activity (80-90%), particularly within the uropod (Fig. 2B ).
Rac1 regulates neutrophil Rho activity in the uropod.
Higher amounts of Rac1G12V produced no further increase in the fraction of cells with active Rho, nor in the intensity of RBD staining. Rac1T17N caused no significant change in the proportion of cells showing some level of active Rho from the controls, although the amount of active Rho present within this population of cells was significantly decreased, particularly within the uropod ( Fig. 2A,B) . This was determined more quantitatively using a pulldown assay based on the Rho binding domain of rhotekin fused to GST 13 2C ). This verifies the coupling of Rac activity to Rho activation observed in the human neutrophils, and suggests that Rac1, but not Rac2, is essential for Rho activation, consistent with a role in stimulating uropod retraction during chemotaxis.
Rac regulates myosin II-mediated contractility through Rho in the uropod.
In order to determine if the requirement for Rac1 signalling to RhoA could account for the observed tail retraction defect, we determined the localization and activation state of myosin using an antibody to phosphorylated (Ser19) myosin regulatory light chain (MLC). Myosin has been previously shown to function in uropod retraction through its role in regulating actin filament contraction. In human neutrophils, we observed that cells expressing Rac1T17N displayed significant inhibition of fMLPstimulated MLC phosphorylation within the uropod (Fig.3A) . This Rac1T17N-mediated suppression of MLC phosphorylation was verified at the biochemical level ( Fig.3B ,C).
Overall levels of MLC phosphorylated at Ser19 were decreased by more than 30% at low levels of Rac1T17N (3-9 µ g/ml), and by nearly 50% at 30 µ g/ml Rac1T17N. Expression suggests that an additional Rac-mediated myosin regulatory mechanism might exist.
Alternatively, spatial considerations resulting from the exogenous reconstitution of RhoA
GTPase might affect efficient coupling to the endogenous myosin-phosphorylating machinery.
Discussion
Migratory cells execute different cytoskeletal programs at their leading and trailing edges under the control of Rho GTPase signaling 1, 11 . While Rac localizes to and is necessary for efficient actin polymerization and protrusion of the leading edge, Rho localizes to and is necessary for myosin-based contraction at the trailing edge. The establishment and maintenance of polarity thus requires communication between Rac and Rho, and these GTPases depend on one another for proper localization and regulation of chemotaxis. Previous studies have focused on the antagonistic relationship between these two GTPases during neutrophil chemotaxis.
Substantial data supports the idea that Rac generally inhibits Rho activity. Global
Rac activation has been shown to inhibit Rho activation in a variety of cells 15, 16 and disruption of signalling to Rac enables the "backness" program to act at the leading edge of HL60 cells 11 , although the relative contribution of Rac1 vs. Rac2 to this effect have not been defined. Conversely, these same studies suggest that Rho locally antagonizes "frontness": Inhibition of Rho produces HL60 cells with multiple leading edges, and global activation of Rho inhibits actin polymerization, Rac activation, and PIP 3 production (another readout of "frontness") 11, 17 . A current model for polarity in neutrophils entails a Gαi-mediated activation of Rac to stimulate F-actin assembly and "frontness", a Gα12/13-mediated activation of Rho to stimulate myosin-based contractility and "backness", and mutual repulsion of these networks to generate a distinct front and back 11 . However, other data suggest that the interaction of Rac and
Rho might not simply be antagonistic. Rac produces cytoskeletal rearrangements consistent with Rho activation in some cell types 18 and receptor-independent activation of the "frontness" program in neutrophils also produces cells with a well-organized trailing edge 19 . Both of these observations suggest that Rac may also positively regulate
Rho.
In the current study, we use primary neutrophils derived from murine transgenic Because of these issues, we therefore complemented these analyses in primary human cells with studies of murine neutrophils in which Rac1 or Rac2 function has been genetically ablated, thereby providing a clean and specific means to evaluate the relative contributions of these two Rac isoforms. It is striking that we obtained very complementary evidence for the regulation of Rho and myosin activation in the uropod by Rac in both the human and murine systems. While the mouse results indicate that it is Rac1 that selectively regulates Rho activity and myosin function, our data do not definitively rule out a contribution of Rac2 to this regulatory pathway, given the abundance of the Rac2 isoform in human neutrophils.
Although we do not yet know the exact molecular mechanism(s) by which Rac1 activity regulates RhoA activity within the uropod, it is clear from our prior work that Rac activation is induced by chemoattractant stimulation both at the front and the rear of the neutrophil 12 , providing a localized source of active Rac within the tail. It is likely that signals generated upon initiation of the chemotactic response are rapidly propagated to modulate Rac activity at both locations, thereby secondarily coordinating Rho activity as well. These data suggest that Rac not only locally inhibits the ""backness"" program at the leading edge, but is also globally required for generation of Rho-myosin mediated ""backness"" at the trailing edge of motile cells. In mouse neutrophils, Rac1 thus plays a key role in linking front to back signalling during neutrophil chemotaxis. This is in contrast to Rac2, which has been previously shown to be the key Rac isoform responsible for regulation of leading edge actin polymerization during chemotaxis, possibly through activation of Cdc42 9 . Differences in the biological effects of Rac1 vs Rac2 in neutrophils have been previously described, and a number of potential mechanisms to explain the different biological activities of these highly similar GTPases have been proposed 5 . Along with the current description of Rac1-specific activation of Rho, these studies begin to outline how these two Rac isoforms differentially regulate key processes during neutrophil chemotaxis.
This dual communication from front to back with Rac1 and/or Rac2 locally inhibiting and Rac1 globally activating Rho-mediated ""backness"" facilitates a more robust balance between these essential polarity programs than is possible with a purely antagonistic relationship. Thus, the effect of chemoattractant-mediated Rac1 activation propagated to the tail to stimulate Rho-mediated myosin activation would promote a proportionally stronger uropod to balance the dynamic primary pseudopod. Such mutual crosstalk would provide a means for chemoattractants to maintain stable polarity during the course of migration to infectious sites. It is of interest in this regard that in our earlier analyses of Rac activation 12 , we observed that while Rac activity was quite dynamic at the front of the neutrophil, it remained relatively constant within the uropod. This 
Methods
Mice
Previously generated and characterized Rac1, Rac2 and double Rac null knockout mice were bred as previously described at the University of Toronto Animal Care Facility
9
.
Briefly Rac1c/-LysMcre were bred with Rac2-/-mice and the resulting offspring were bred over at least 6 generations to generate optimal breeding pairs (Rac1c/-LysMcreRac2+/-x Rac1c/-LysM-Rac2+/-), which would enable the generation of Rac1 null (Rac1c/-LysMcreRac2+/+), Rac2 null (Rac1+/+LysMcreRac2-/-), Rac1/2 null (Rac1c/-LysMcreRac2-/-), and wild-type mice (Rac1+/+LysMcre Rac2+/+) from the same litters. Rac1 is disrupted in a granulocyte/neutrophil-specific fashion by breeding of mice carrying a loxP-flanked Rac1 allele with LysMcre mice in which the Crerecombinase is expressed under control of the murine lysozyme M gene regulatory region, which is active during early embryogenesis 6 . Using this approach Rac1 is deleted in the neutrophils from birth. All experiments were performed with mice 6 to 13 weeks old. This breeding strategy allows for the controlling of background variations and control experiments confirmed that LysMcre expression did not affect any neutrophil functions including bacterial killing when compared to controls. Genotyping for Rac1, Rac2, and LysM alleles was carried out as described previously 9 . All procedures were carried out in accordance with the Guide for the Humane Use and Care of Laboratory Animals and were approved by the University of Toronto Animal Care Committee.
Mouse neutrophil preparations
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Mature neutrophils were recovered at the 82%/65% interface and were positive for Gr-1
and Mac-1 as shown by flow cytometry. More than 85% of the isolated cells were neutrophils as assessed by Wright-Giemsa staining. Viability as determined by trypan blue exclusion was greater than 90%.
Rhotekin assay for active Rho
The Rhotekin (Rho) binding domain (RBD) pulldown affinity assay was carried out as described previously 13 . Briefly, isolated bone marrow (or human) neutrophils were exposed to fMLP at 37°C for the indicated times. They were immediately lysed and GST-RBD-glutathione beads were added to the lysates. The GST-RBD was recovered and immunoblotting was completed using RhoA (sc-418) antibody (Santa Cruz Biotechnology). Image J software version 1.31v (National Institutes of Health) was used for blot densitometry. Data was normalized to resting wild-type neutrophils and are expressed as the mean from 3 separate experiments.
Human neutrophil chemotaxis and de-adhesion assays
Human neutrophils were isolated from blood collected from normal human subjects as described earlier 21 . The cells were suspended in chemotaxis buffer (140 mM KCl, 10 mM glucose, 10 mM HEPES, 1 mM EGTA, 1 mM MgCl 2 and 189 µ M CaCl 2 ), and allowed to attach to coverslips coated with human serum albumin (0.2% in saline).
Chemotaxis assays were carried out with live cells essentially as described 12 . The percentage of cells that are able to migrate freely towards the point source over the 15 min duration was used as a measure of chemotaxis. This ranged from 30 to 60% of the total cell population in various neutrophil preparations from distinct donors. Movements of 40 -100 cells per field were tracked for each treatment. Values shown are an average from 4-8 experiments. Cells that were clearly able to sense the gradient but unable to move from the original spot due to their inability to retract their uropods were also counted. To study de-adhesion, neutrophils were allowed to attach to the bottom of plastic 96 well plates coated with human serum albumin, and transduced with protein as described below. After removing the buffer, the wells were gently washed once with chemotaxis buffer, the adherent cells fixed with paraformaldehyde, then counted visually under the microscope.
Expression of proteins in human neutrophils
Rac1 and RhoA glutathione-S-transferase (GST)-fusion proteins were expressed in E.
coli, purified on glutathione beads, and the expressed protein cleaved off using thrombin according to manufacturers instructions 12 . The purified proteins were mixed with the appropriate concentration of Bioporter reagent, and pipetted onto coverslips of spread neutrophils. Under these conditions, we determined that ~90% of the cells took up protein 12 . Unless specified, a protein concentration of 9 µ g/ml for the dominant negative proteins, or 12 µ g/ml for the constitutively active protein was used in all the experiments described here. These concentrations gave cellular GTPase concentrations 1-2-fold the level of endogenous Rac2
12
. The cells were incubated at room temperature with the mixture for 2-3 hrs as per manufacturers instructions (Gene Therapy Systems, San Diego, CA). Neutrophils were either stimulated globally (10 µ M fMLP, 5 mins), then fixed with 4% paraformaldehyde and used for immunostaining, or mounted on Attofluor-live-cell chambers (Molecular Probes) and stimulated with an fMLP point source (supplied by micropipette) to measure chemotaxis, as described earlier 12 .
Staining with myosin antibodies and Rhotekin Rho-binding domain (RBD)
Immunostaining for myosin heavy chain (MHC) and phosphorylated myosin light chain 
D. Myosin II phosphorylation requires Rac1 activity in mouse neutrophils.
Quantitation of immunoblots of phospho-myosin II regulatory light chain (MLC) in bone marrow neutrophils exposed to fMLP (1µM). FMLP-mediated phospho-MLC level increases in a similar pattern in wild-type and Rac2 null neutrophils over 120 seconds, but is severely perturbed in Rac1 null neutrophils.
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